Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology
company developing a liposomal delivery technology for nucleic acid
cancer drugs, today announced that Peter Nielsen, President and Chief
Executive Officer, will present a company overview at the 13 th
Annual BIO Investor Forum Conference in San Francisco on Tuesday,
October 7, 2014 at 10:00 a.m. Pacific Time (1:00pm Eastern Time).
The overview will include an update on Cohort 6 of the Phase I clinical
trial evaluating Grb-2 in blood cancers, in which the last patient in
the cohort has been treated and is evaluable.
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused
on the development of therapeutics to treat kidney disease, today
announced that Pierre Legault, Chief Executive Officer, will present a
corporate overview of the Company and meet with investors at the 13 th
annual Bio Investor Forum at the Palace Hotel in San Francisco.
Sevion Therapeutics (OTCQB:SVON), a clinical stage company which
discovers, develops and acquires next-generation biologics for the
treatment of cancer and immunological diseases, announced today that
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.